Artal Group S.A. lifted its holdings in ProQR Therapeutics NV (NASDAQ:PRQR) by 26.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,900,000 shares of the biopharmaceutical company’s stock after acquiring an additional 400,000 shares during the quarter. Artal Group S.A. owned approximately 0.06% of ProQR Therapeutics worth $6,128,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. Nine Chapters Capital Management LLC acquired a new position in shares of ProQR Therapeutics in the 3rd quarter worth approximately $133,000. Wells Fargo & Company MN boosted its holdings in shares of ProQR Therapeutics by 212.6% in the 3rd quarter. Wells Fargo & Company MN now owns 43,226 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 29,400 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of ProQR Therapeutics in the 2nd quarter worth approximately $2,028,000. Sphera Funds Management LTD. boosted its holdings in shares of ProQR Therapeutics by 60.6% in the 3rd quarter. Sphera Funds Management LTD. now owns 530,000 shares of the biopharmaceutical company’s stock worth $2,571,000 after acquiring an additional 200,000 shares in the last quarter. Finally, Jennison Associates LLC boosted its holdings in shares of ProQR Therapeutics by 7.3% in the 4th quarter. Jennison Associates LLC now owns 2,635,552 shares of the biopharmaceutical company’s stock worth $8,500,000 after acquiring an additional 178,192 shares in the last quarter. 32.18% of the stock is currently owned by institutional investors and hedge funds.
ProQR Therapeutics NV (NASDAQ:PRQR) opened at $3.50 on Friday. ProQR Therapeutics NV has a 1-year low of $2.75 and a 1-year high of $6.90. The company has a current ratio of 6.72, a quick ratio of 6.72 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $109.92, a price-to-earnings ratio of -1.84 and a beta of 0.60.
ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings data on Monday, November 20th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.03. equities analysts expect that ProQR Therapeutics NV will post -2.06 earnings per share for the current year.
PRQR has been the topic of several recent analyst reports. Zacks Investment Research downgraded ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Chardan Capital reaffirmed a “neutral” rating on shares of ProQR Therapeutics in a report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. ProQR Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $18.88.
COPYRIGHT VIOLATION WARNING: “ProQR Therapeutics NV (PRQR) Stake Lifted by Artal Group S.A.” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/18/proqr-therapeutics-nv-prqr-stake-lifted-by-artal-group-s-a.html.
About ProQR Therapeutics
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.
Want to see what other hedge funds are holding PRQR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProQR Therapeutics NV (NASDAQ:PRQR).
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.